- As China Slows Down, the Philippines Moves to Grab Foreign Investment
- Why Obamacare Subsidies Should Be Struck Down by the Supreme Court
- 15 Cheap Cities Where You Don't Need a High Salary to Buy a House
- MannKind's Afrezza Earns Lackluster Review from Independent Drug Arbiter
- Shale Oil Bust Enters Phase Two, Led by Hercules and SandRidge
A panel of experts is debating the merits of Chelsea's drug as a treatment for a debilitating form of low blood pressure. Follow along with our live blog.
An FDA panel's decision on the safety of calcitonin to treat osteoporosis will have a big impact on Unigene's stock price.
TheStreet contributor Aafia Chaudhry says prior study results raise the risk of a bad outcome in Ziopharm's phase III sarcoma drug trial.
Eteplirsen data are biased and flimsy, and FDA will ask for another clinical trial, says TheStreet contributor Aafia Chaudhry.
New contributor Aafia Chaudhry explains why she believes Depomed's hot flash drug has no future.